Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

EXPERT REVIEWS IN MOLECULAR MEDICINE, published by Cambridge University Press, stands at the forefront of research in the fields of Molecular Biology and Molecular Medicine. With an impressive impact factor reflecting its Q1 status in both relevant categories, this journal serves as an essential platform for disseminating cutting-edge reviews and critical assessments that are vital for advancing our understanding of molecular mechanisms in health and disease. Established in 1997 and continuously evolving until 2024, it features contributions from leading experts that highlight emerging trends and innovative methodologies. Researchers, professionals, and students are encouraged to engage with the content, benefiting from the journal’s rigorous peer-review process and its commitment to academic excellence, making it a valuable resource within the scientific community.

BIOCHEMICAL JOURNAL, published by Portland Press Ltd, stands as a leading publication in the fields of Biochemistry, Cell Biology, and Molecular Biology, reflecting a commitment to advancing scientific knowledge since its inception in 1945. With a distinguished Q1 ranking across these categories and impressive Scopus rankings, the journal serves as an invaluable resource for researchers, professionals, and students alike, facilitating critical discoveries and innovative research practices. Although not currently offering open access, the journal provides a platform for high-quality peer-reviewed articles, ensuring rigorous standards in the dissemination of biochemical research. Spanning over seven decades and continuing through to 2024, the BIOCHEMICAL JOURNAL fosters an environment where cutting-edge biochemical research thrives, supporting the global scientific community's efforts to address complex biological questions and enhance our understanding of fundamental cellular processes.

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

PPAR Research, an esteemed journal published by HINDAWI LTD, specializes in the rapidly evolving fields of drug discovery and pharmacology, contributing significantly to the body of research surrounding peroxisome proliferator-activated receptors (PPARs) and their roles in various biochemical processes. With an open access policy implemented since 2006, the journal ensures that its high-quality content is readily available, promoting widespread dissemination of knowledge. Currently ranked in the Q2 category for both Drug Discovery and Medical Pharmacology, it boasts a respectable position within the scientific community, evidenced by its Scopus rankings. PPAR Research serves as an essential resource for researchers, professionals, and students looking to advance their understanding of PPAR biology and its implications in therapeutic development. The journal's commitment to excellence and accessibility makes it a key player in supporting innovative research and critical discussions in the life sciences.

Frontiers in Bioscience-Landmark is a prestigious journal published by IMR PRESS that focuses on a diverse array of topics within the fields of biochemistry, genetics, molecular biology, immunology, and microbiology. With the ISSN 2768-6701 and E-ISSN 2768-6698, this journal has carved a significant niche since its inception in 1996, making its mark in contributions to the scientific community all the way through to 2024. Having achieved a respectable Q2 cohort rank in multiple categories, including biochemistry and immunology, it stands out for its impactful research, evidenced by its current Scopus rankings which highlight it as a vital resource for ongoing studies and advancements in the biosciences. Despite not being open access, the journal ensures that readers have access to high-quality research articles that are peer-reviewed and designed to foster academic discourse. The importance of Frontiers in Bioscience-Landmark lies in its commitment to disseminating innovative findings that can significantly enhance our understanding of biological sciences, making it an essential read for researchers, professionals, and students alike.

Cancer Drug Resistance is a premier journal published by OAE PUBLISHING INC, focusing on the critical field of oncology and pharmacology. Since its inception in 2018, the journal has been at the forefront of presenting innovative research aimed at understanding and overcoming drug resistance in cancer therapy. With an impressive impact factor reflected in its Q2 ranking in Cancer Research and a Q1 ranking in Pharmacology (medical) for 2023, Cancer Drug Resistance serves as a vital resource for researchers, clinicians, and students who are dedicated to advancing cancer treatment and improving patient outcomes. The journal's commitment to disseminating high-quality, peer-reviewed articles underscores its importance within the academic and medical communities. While it operates on an open-access model, facilitating widespread distribution and access to crucial research findings, the journal continuously strives to foster dialogue and collaboration among stakeholders in cancer research and pharmacology. Its mission is clear: to shine a light on the evolving challenges and breakthroughs in drug resistance, paving the way for enhanced therapeutic strategies and clinical solutions.

Cell Metabolism is an esteemed journal published by CELL PRESS, dedicated to advancing the understanding of metabolic processes within cell biology, molecular biology, and physiology. With an impactful 2023 ranking placing it at Q1 in multiple categories and earning a distinguished position in the top percentiles of its respective fields, this journal serves as an essential resource for researchers, professionals, and students who are investigating the dynamic roles of metabolism in health and disease. Its rigorous peer-review process ensures high-quality publications that reflect the latest advancements in metabolic research. Since its inception in 2005, Cell Metabolism has become a pivotal platform for disseminating critical findings that not only expand scientific knowledge but also foster innovative approaches to tackle metabolic disorders. By prioritizing accessibility and scholarly excellence without the Open Access model, it remains a premier source for cutting-edge research insights.

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.